Meridian Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Meridian Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-854	Closed	-$480K	–	242
2025 Q3	$480K	Hold	854	–	–	0.12%	155
2025 Q2	$448K	Hold	854	–	–	0.12%	150
2025 Q1	$542K	Hold	854	–	–	0.16%	134
2024 Q4	$608K	Hold	854	–	–	0.18%	121
2024 Q3	$898K	Hold	854	–	–	0.27%	96
2024 Q2	$898K	Hold	854	–	–	0.28%	91
2024 Q1	$822K	Sell	854 -35	-4%	-$33.3K	0.27%	92
2023 Q4	$781K	Hold	889	–	–	0.27%	89
2023 Q3	$732K	Buy	889 +1	+0.1%	+$786	0.27%	91
2023 Q2	$638K	Hold	888	–	–	0.23%	105
2023 Q1	$730K	Hold	888	–	–	0.28%	93
2022 Q4	$641K	Hold	888	–	–	0.26%	103
2022 Q3	$612K	Hold	888	–	–	0.27%	98
2022 Q2	$525K	Sell	888 -70	-7%	-$45.5K	0.22%	111
2022 Q1	$669K	Hold	958	–	–	0.23%	109
2021 Q4	$605K	Buy	+958	New	+$589K	0.2%	111

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Meridian Investment Counsel's REGN Position: Q4 2025 in Review

Meridian Investment Counsel sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 854 shares — an estimated $480K sold.

Meridian Investment Counsel first reported a position in REGN in Q4 2021 and held it in 16 quarters. The position peaked at $898K in Q3 2024. 1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Meridian Investment Counsel reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Meridian Investment Counsel sold 854 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $480K.
Meridian Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 16 quarters.
Meridian Investment Counsel's Regeneron Pharmaceuticals position peaked at $898K in Q3 2024.
1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Meridian Investment Counsel's 13F filing for Q4 2025, filed 20 Jan 2026.